Structure Search


    Online Support

  •  Customer service

    Location: Industrial Info

Type 3 Diabetes——AD, could be treated with diabetes drug?

2018-01-02 来源:转载自第三方
2 January 2018
  Recently, scientists from Lancaster University in the UK found that the combination of three drugs for treating type 2 diabetes can effectively improve memory impairment symptoms in Alzheimer's mouse model. This study has been published in the international journal "Brain Research" entitled "Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease."
  Diabetes is a chronic disease that occurs when the pancreas does not produce enough insulin or the body can not effectively utilize the insulin it produces. We all know that there are two types of diabetes—type 1 and type 2 diabetes. The etiology of type 1 diabetes is not clear, the use of existing knowledge can not be prevented, characterized by a lack of insulin secretion; type 2 diabetes is due to the body can not effectively use insulin, mainly due to the wrong diet and lifestyle, It is completely preventable. However, diabetes can occur not only in the body, but also in the brain. Scientists call diabetes, which occurs in the brain, type 3 diabetes, and its clinical condition is Alzheimer's disease (AD).
  For Type 1 and Type 2 diabetes, there are currently a variety of drugs such as insulin, α-glucosidase inhibitors, sulfonylureas, biguanides, glinides, as well as those new drugs that act on DPP-4, GLP-1, SGLT-2 and other targets; for type 3 diabetes—Alzheimer's disease, there are also cholinesterase inhibitors, anti-amyloid β proteins, anti-tau phosphorylation and other drugs. So, since Alzheimer's disease is type 3 diabetes, do drugs for type 1 and type 2 diabetes have an effect on AD?
  In previous studies, scientists have found abnormalities in the pathways associated with three types of growth factors, including GLP-1, GIP, and glucagon receptor agonists, in brain neurons of patients with Alzheimer's disease. So in the study, scientists combined these three classes of growth factors and used maze tests to test whether the therapy regained the cognitive ability of Alzheimer's mice. The results showed that the learning and cognitive abilities of the treated mice were improved; the rate of neuron reduction, the inflammatory response and the oxidative stress response were significantly reduced in the brain; the amyloid aggregation in the brain was significantly reduced; the neurogenesis in the brain, Neurotrophic factor expression and number of synapses have been elevated. However, the triple-drug regimen is far from reaching the clinical stage of research and more research still needs to be done to determine if it's worth going any further.
  Alzheimer's disease is a terrible disease that the patient not only loses health but also loses the dignity and also places a heavy burden on the relatives. This discovery by scientists may make a huge contribution to the prevention and treatment of Alzheimer's disease and we look forward to further research reports.
[1] Jingjing Tai,Weizhen Liu,Yanwei Li,et al. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease. Brain Research, 2018, 1678, 64-74.
Edited by Suzhou Yacoo Science Co., Ltd.